V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Biohaven Executive Compensation (FY25)

BHVN · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Vlad Coric
Latest say-on-pay support
=
April 28, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Biohaven brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 19, 2026Latest filing (8-K): May 4, 2026
4 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Biohaven brief$1,500Get the executive brief
Velarion Member, one year
201 figures on this page: 199 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Vlad Coric: $10,479,038 → $13,500,438 (28.8% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Biohaven's chief executive and what were they paid?
Vlad Coric was paid $13,500,438 in total compensation as Chief Executive Officer for fiscal 2025. Coric's total was 28.8% higher than the $10,479,038 reported for fiscal 2024.
What was Biohaven's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 95.4% of votes cast for or against in favor at the meeting held April 28, 2026.
Which companies are in Biohaven's peer group?
The disclosed peer group includes Anaptys Bio, Apellis Pharmaceuticals, Arrowhead Pharmaceuticals, Arvinas and Axsome Therapeutics, among others.
What is Biohaven's chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 25:1, against median employee compensation of $529,257.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Vlad Coric
Chief Executive Officer
◇◇—◇——◇◇
Matthew Buten
Chief Financial Officer
◇◇—◇——◇◇
Bruce Car
Chief Scientific Officer
◇◇—◇——◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Vlad Coric
Chief Executive Officer
◇◇—◇——◇◇
Matthew Buten
Chief Financial Officer
◇◇—◇——◇◇
Bruce Car
Chief Scientific Officer
◇◇—◇——◇◇
Kimberly Gentile
Senior Vice President, Clinical Operations
◇◇—◇——◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Vlad Coric
Chief Executive Officer
◇◇—◇——◇◇
Matthew Buten
Chief Financial Officer
◇◇—◇——◇◇
Bruce Car
Chief Scientific Officer
◇◇—◇——◇◇
Kimberly Gentile
Senior Vice President, Clinical Operations
◇◇—◇——◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Vlad Coric
Chief Executive Officer
◇◇◇◇——◇◇
Bruce Car
Chief Scientific Officer
◇◇◇◇——◇◇
Matthew Buten
Chief Financial Officer
◇◇◇◇——◇◇
Kimberly Gentile
Senior Vice President, Clinical Operations
◇◇◇◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Bruce CarRSU◇——◇——◇
Bruce CarOPTION◇——◇—◇◇
Kimberly GentileOPTION◇——◇—◇◇
Kimberly GentileRSU◇——◇——◇
Matthew ButenOPTION◇——◇—◇◇
Matthew ButenRSU◇——◇——◇
Vlad CoricRSU◇——◇——◇
Vlad CoricOPTION◇——◇—◇◇
Fiscal 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Bruce CarOption◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
Matthew ButenOption◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
Vlad CoricRSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Kimberly GentileRSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Bruce Car
Chief Scientific Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Kimberly Gentile
Senior Vice President, Clinical Operations · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Change-in-control base◇
Matthew Buten
Chief Financial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Vlad Coric
Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael T. Heffernan
Lead independent director
◇—◇———◇
Julia P. Gregory
◇—◇———◇
John W. Childs
◇—◇———◇
Gregory H. Bailey
◇—◇———◇
Robert J. Hugin
◇—◇———◇
Irina Antonijevic
◇—◇———◇
Kishan Mehta
◇—◇———◇
Vlad Coric served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Anaptys Bio ANAB
  • Apellis Pharmaceuticals APLS
  • Arrowhead Pharmaceuticals ARWR
  • Arvinas ARVN
  • Axsome Therapeutics AXSM
  • BridgeBio Pharma BBIO
  • Cogent Biosciences COGT
  • Crinetics Pharmaceuticals CRNX
  • Denali Therapeutics DNLI
  • ImmunityBio IBRX
  • Immunovant IMVT
  • Intra-Cellular Therapies ITCI
  • Iovance Biotherapeutics IOVA
  • Longboard Pharmaceuticals LBPH
  • Neumora Therapeutics NMRA
  • Rhythm Pharmaceuticals RYTM
  • Sage Therapeutics SAGE
  • Vera Therapeutics VERA
  • Vir Biotechnology VIR
  • Xencor XNCR
  • Xenon Pharmaceuticals XENE

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025April 28, 2026=◇◇◇
2024May 5, 2025=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Vlad Coric (Chief Executive Officer), FY2025 total compensation $13,500,438 (base salary $920,400) [exec_comp, SEC accession 0001935979-26-000028, filed 2026-03-13]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Biohaven files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Biohaven disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Biohaven sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Biohaven's disclosed peer group is defensible, who names Biohaven back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
201 figures on this page: 199 cited to the filing that reported them, 2 calculated from figures it prints.
199 cited to the filing
2 calculated from the filing

Documents cited

  1. 0001935979-26-000042
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001935979-26-000028
    Compensation Discussion and Analysis · DIRECTOR COMPENSATION · EXECUTIVE COMPENSATION PROGRAM IN DETAIL · GRANTS OF PLAN-BASED AWARDS IN 2025 · and 2 more sections
  3. 0001935979-25-000049
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001935979-23-000011
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Biohaven executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/BHVN (accessed 2026).
Short form: data: Velarion

The Biohaven brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
4 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Biohaven and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Biohaven discloses

The companies named in BHVN's own disclosed peer group.

Anaptys BioApellis PharmaceuticalsArrowhead PharmaceuticalsArvinasAxsome TherapeuticsBridgeBio PharmaCogent BiosciencesCrinetics PharmaceuticalsDenali TherapeuticsImmunityBioImmunovantIntra-Cellular TherapiesIovance BiotherapeuticsLongboard PharmaceuticalsNeumora TherapeuticsRhythm PharmaceuticalsSage TherapeuticsVera TherapeuticsVir BiotechnologyXencorXenon Pharmaceuticals

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy